Neurocognitive function and survival in children with average-risk medulloblastoma treated with hyperfractionated radiation therapy alone: Long-term mature outcomes of a prospective study.
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-oncology practice"
DOI: 10.1093/nop/npac020
Abstract: Background The purpose of this study was to report long-term neurocognitive and clinical outcomes in children treated for average-risk medulloblastoma with hyperfractionated radiation therapy (HFRT) alone. Methods Between 2006 and 2010, 20 children with rigorously… read more here.
Keywords: survival; term; average risk; risk medulloblastoma ... See more keywords
Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.20.02730
Abstract: PURPOSE Children with average-risk medulloblastoma (MB) experience survival rates of ≥ 80% at the expense of adverse consequences of treatment. Efforts to mitigate these effects include deintensification of craniospinal irradiation (CSI) dose and volume. METHODS… read more here.
Keywords: risk medulloblastoma; average risk; volume; oncology ... See more keywords
Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14020374
Abstract: Simple Summary Patients with medulloblastoma receive treatment according to a risk stratification, which is a combination of clinical and biological factors. To date there have been a limited number of trials for high-risk disease in… read more here.
Keywords: trials high; high risk; trial; risk medulloblastoma ... See more keywords